Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 9033 entries
Sorted by: Best Match Show Resources per page
KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings

community settings

Webster J.
GSID: yCKyzQYLCigJ
J Webster, TL Kauffman, HS Feigelson… - Cancer Epidemiology …, 2013 - AACR

Background: In metastatic colorectal cancer (mCRC), mutations in the KRAS gene predict poor response to EGF receptor (EGFR) inhibitors. Clinical treatment guidelines now recommend KRAS testing if EGFR inhibitors are considered. Our study investigates the clinical uptake …

Cite
Webster, J., Kauffman, T. L., Feigelson, H. S., Pawloski, P. A., Onitilo, A. A., Potosky, A. L., ... & CERGEN study team. (2013). KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiology and Prevention Biomarkers, 22(1), 91-101.
Webster, Jennifer, et al. "KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings." Cancer Epidemiology and Prevention Biomarkers 22.1 (2013): 91-101.
Copy Download .nbib Format: MLA
Factors associated with guideline-recommended KRAS testing in colorectal cancer patients: a population-based study

community settings

[No authors listed]
GSID: heL1kmDUpWcJ
ME Charlton, JJ Karlitz, JA Schlichting… - American journal of …, 2017 - ncbi.nlm.nih.gov

Objectives Response to epidermal growth factor receptor inhibitors is poorer among Stage IV colorectal cancer (CRC) patients with KRAS mutations, thus KRAS testing is …

Cite
Charlton, M. E., Karlitz, J. J., Schlichting, J. A., Chen, V. W., & Lynch, C. F. (2017). Factors associated with guideline-recommended KRAS testing in colorectal cancer patients: a population-based study. American journal of clinical oncology, 40(5), 498.
Charlton, Mary E., et al. "Factors associated with guideline-recommended KRAS testing in colorectal cancer patients: a population-based study." American journal of clinical oncology 40.5 (2017): 498.
Copy Download .nbib Format: MLA
Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer.

OncoTargets and therapy

Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K.
PMID: 24124381
Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013.

Bevacizumab when combined with chemotherapy exerts significant activity against many solid tumors through tumor angiogenesis inhibition; however, it can induce severe side effects. We report the rare case of a 27-year-old premenopausal woman with locally advanced breast cancer that...

Cite
Ono M, Ito T, Kanai T, et al. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013;6:1393-8doi: 10.2147/OTT.S51164.
Ono, M., Ito, T., Kanai, T., Murayama, K., Koyama, H., Maeno, K., Mochizuki, Y., Iesato, A., Hanamura, T., Okada, T., Watanabe, T., & Ito, K. (2013). Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. OncoTargets and therapy, 61393-8. https://doi.org/10.2147/OTT.S51164
Ono, Mayu, et al. "Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer." OncoTargets and therapy vol. 6 (2013): 1393-8. doi: https://doi.org/10.2147/OTT.S51164
Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther. 2013 Oct 07;6:1393-8. doi: 10.2147/OTT.S51164. eCollection 2013. PMID: 24124381; PMCID: PMC3794845.
Copy Download .nbib Format: NLM
Molecular recognition of gangliosides and their potential for cancer immunotherapies.

Frontiers in immunology

Krengel U, Bousquet PA.
PMID: 25101077
Front Immunol. 2014 Jul 21;5:325. doi: 10.3389/fimmu.2014.00325. eCollection 2014.

Gangliosides are sialic-acid-containing glycosphingolipids expressed on all vertebrate cells. They are primarily positioned in the plasma membrane with the ceramide part anchored in the membrane and the glycan part exposed on the surface of the cell. These lipids have...

Cite
Krengel U, Bousquet PA. Molecular recognition of gangliosides and their potential for cancer immunotherapies. Front Immunol. 2014;5:325doi: 10.3389/fimmu.2014.00325.
Krengel, U., & Bousquet, P. A. (2014). Molecular recognition of gangliosides and their potential for cancer immunotherapies. Frontiers in immunology, 5325. https://doi.org/10.3389/fimmu.2014.00325
Krengel, Ute, and Bousquet, Paula A. "Molecular recognition of gangliosides and their potential for cancer immunotherapies." Frontiers in immunology vol. 5 (2014): 325. doi: https://doi.org/10.3389/fimmu.2014.00325
Krengel U, Bousquet PA. Molecular recognition of gangliosides and their potential for cancer immunotherapies. Front Immunol. 2014 Jul 21;5:325. doi: 10.3389/fimmu.2014.00325. eCollection 2014. PMID: 25101077; PMCID: PMC4104838.
Copy Download .nbib Format: NLM
Liver regeneration and aging: a current perspective.

Current gerontology and geriatrics research

Schmucker DL, Sanchez H.
PMID: 21912543
Curr Gerontol Geriatr Res. 2011;2011:526379. doi: 10.1155/2011/526379. Epub 2011 Sep 08.

Many organ systems exhibit significant age-related deficits, but, based on studies in old rodents and elderly humans, the liver appears to be relatively protected from such changes. A remarkable feature of the liver is its capacity to regenerate its...

Cite
Schmucker DL, Sanchez H. Liver regeneration and aging: a current perspective. Curr Gerontol Geriatr Res. 2011;2011:526379doi: 10.1155/2011/526379.
Schmucker, D. L., & Sanchez, H. (2011). Liver regeneration and aging: a current perspective. Current gerontology and geriatrics research, 2011526379. https://doi.org/10.1155/2011/526379
Schmucker, Douglas L, and Sanchez, Henry. "Liver regeneration and aging: a current perspective." Current gerontology and geriatrics research vol. 2011 (2011): 526379. doi: https://doi.org/10.1155/2011/526379
Schmucker DL, Sanchez H. Liver regeneration and aging: a current perspective. Curr Gerontol Geriatr Res. 2011;2011:526379. doi: 10.1155/2011/526379. Epub 2011 Sep 08. PMID: 21912543; PMCID: PMC3170699.
Copy Download .nbib Format: NLM
Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib.

OncoTargets and therapy

Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, Wu X, Lu Y, Bai H, Xu J, Zhu G, Zhang L.
PMID: 23251095
Onco Targets Ther. 2012;5:439-47. doi: 10.2147/OTT.S37289. Epub 2012 Dec 12.

BACKGROUND: Previous studies have reported that epidermal growth factor receptor (EGFR) mutation in tumor tissue and peripheral blood can predict the response to EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). However, the heterogeneity of the...

Cite
Xu F, Wu J, Xue C, et al. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther. 2012;5:439-47doi: 10.2147/OTT.S37289.
Xu, F., Wu, J., Xue, C., Zhao, Y., Jiang, W., Lin, L., Wu, X., Lu, Y., Bai, H., Xu, J., Zhu, G., & Zhang, L. (2012). Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. OncoTargets and therapy, 5439-47. https://doi.org/10.2147/OTT.S37289
Xu, Fei, et al. "Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib." OncoTargets and therapy vol. 5 (2012): 439-47. doi: https://doi.org/10.2147/OTT.S37289
Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, Wu X, Lu Y, Bai H, Xu J, Zhu G, Zhang L. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther. 2012;5:439-47. doi: 10.2147/OTT.S37289. Epub 2012 Dec 12. PMID: 23251095; PMCID: PMC3525047.
Copy Download .nbib Format: NLM
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.

Breast cancer (Dove Medical Press)

Jerusalem G, Rorive A, Collignon J.
PMID: 24833916
Breast Cancer (Dove Med Press). 2014 Apr 17;6:43-57. doi: 10.2147/BCTT.S38679. eCollection 2014.

Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents. Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an...

Cite
Jerusalem G, Rorive A, Collignon J. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer (Dove Med Press). 2014;6:43-57doi: 10.2147/BCTT.S38679.
Jerusalem, G., Rorive, A., & Collignon, J. (2014). Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast cancer (Dove Medical Press), 643-57. https://doi.org/10.2147/BCTT.S38679
Jerusalem, Guy, et al. "Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes." Breast cancer (Dove Medical Press) vol. 6 (2014): 43-57. doi: https://doi.org/10.2147/BCTT.S38679
Jerusalem G, Rorive A, Collignon J. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer (Dove Med Press). 2014 Apr 17;6:43-57. doi: 10.2147/BCTT.S38679. eCollection 2014. PMID: 24833916; PMCID: PMC4000187.
Copy Download .nbib Format: NLM
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.

OncoTargets and therapy

Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, Zhang J, Ma Y, Zhou T, Qin T, Zhang L.
PMID: 24204163
Onco Targets Ther. 2013 Oct 21;6:1481-91. doi: 10.2147/OTT.S51887. eCollection 2013.

BACKGROUND: Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are widely used for EGFR mutated non-small-cell lung cancer (NSCLC) patients, tumor sample availability and heterogeneity of the tumor remain challenging for physicians' selection of these patients. Here, we...

Cite
Wu X, Liang W, Hou X, et al. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. Onco Targets Ther. 2013;6:1481-91doi: 10.2147/OTT.S51887.
Wu, X., Liang, W., Hou, X., Lin, Z., Zhao, H., Huang, Y., Fang, W., Zhao, Y., Wu, J., Yang, Y., Xue, C., Hu, Z., Zhang, J., Zhang, J., Ma, Y., Zhou, T., Qin, T., & Zhang, L. (2013). Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. OncoTargets and therapy, 61481-91. https://doi.org/10.2147/OTT.S51887
Wu, Xuan, et al. "Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC." OncoTargets and therapy vol. 6 (2013): 1481-91. doi: https://doi.org/10.2147/OTT.S51887
Wu X, Liang W, Hou X, Lin Z, Zhao H, Huang Y, Fang W, Zhao Y, Wu J, Yang Y, Xue C, Hu Z, Zhang J, Zhang J, Ma Y, Zhou T, Qin T, Zhang L. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. Onco Targets Ther. 2013 Oct 21;6:1481-91. doi: 10.2147/OTT.S51887. eCollection 2013. PMID: 24204163; PMCID: PMC3818102.
Copy Download .nbib Format: NLM
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

American journal of cancer research

Lin Y, Wang X, Jin H.
PMID: 25232485
Am J Cancer Res. 2014 Sep 06;4(5):411-35. eCollection 2014.

The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that plays a critical role in the initiation and development of malignant tumors via modulating downstream signaling pathways. In non-small cell lung cancer (NSCLC), the...

Cite
Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res. 2014;4(5):411-35
Lin, Y., Wang, X., & Jin, H. (2014). EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. American journal of cancer research, 4(5), 411-35.
Lin, Yuxin, et al. "EGFR-TKI resistance in NSCLC patients: mechanisms and strategies." American journal of cancer research vol. 4,5 (2014): 411-35.
Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res. 2014 Sep 06;4(5):411-35. eCollection 2014. PMID: 25232485; PMCID: PMC4163608.
Copy Download .nbib Format: NLM
EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast.

Korean journal of pathology

Hwangbo W, Lee JH, Ahn S, Kim S, Park KH, Kim CH, Kim I.
PMID: 23667369
Korean J Pathol. 2013 Apr;47(2):107-15. doi: 10.4132/KoreanJPathol.2013.47.2.107. Epub 2013 Apr 24.

BACKGROUND: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment.METHODS: A total of 706 invasive ductal carcinomas (IDC)...

Cite
Hwangbo W, Lee JH, Ahn S, et al. EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean J Pathol. 2013;47(2):107-15doi: 10.4132/KoreanJPathol.2013.47.2.107.
Hwangbo, W., Lee, J. H., Ahn, S., Kim, S., Park, K. H., Kim, C. H., & Kim, I. (2013). EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean journal of pathology, 47(2), 107-15. https://doi.org/10.4132/KoreanJPathol.2013.47.2.107
Hwangbo, Won, et al. "EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast." Korean journal of pathology vol. 47,2 (2013): 107-15. doi: https://doi.org/10.4132/KoreanJPathol.2013.47.2.107
Hwangbo W, Lee JH, Ahn S, Kim S, Park KH, Kim CH, Kim I. EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean J Pathol. 2013 Apr;47(2):107-15. doi: 10.4132/KoreanJPathol.2013.47.2.107. Epub 2013 Apr 24. PMID: 23667369; PMCID: PMC3647122.
Copy Download .nbib Format: NLM
The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma.

Contemporary oncology (Poznan, Poland)

Richter I, Dvořák J, Urbanec M, Bluml A, Čermáková E, Bartoš J, Petera J.
PMID: 26199571
Contemp Oncol (Pozn). 2015;19(1):48-53. doi: 10.5114/wo.2015.50013. Epub 2015 Mar 26.

AIM OF THE STUDY: The aim of this retrospective study was to determine the prognostic impact of epidermal growth factor receptor (EGFR) expression changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.MATERIAL AND METHODS: Fifty patients with...

Cite
Richter I, Dvořák J, Urbanec M, et al. The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Contemp Oncol (Pozn). 2015;19(1):48-53doi: 10.5114/wo.2015.50013.
Richter, I., Dvořák, J., Urbanec, M., Bluml, A., Čermáková, E., Bartoš, J., & Petera, J. (2015). The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Contemporary oncology (Poznan, Poland), 19(1), 48-53. https://doi.org/10.5114/wo.2015.50013
Richter, Igor, et al. "The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma." Contemporary oncology (Poznan, Poland) vol. 19,1 (2015): 48-53. doi: https://doi.org/10.5114/wo.2015.50013
Richter I, Dvořák J, Urbanec M, Bluml A, Čermáková E, Bartoš J, Petera J. The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Contemp Oncol (Pozn). 2015;19(1):48-53. doi: 10.5114/wo.2015.50013. Epub 2015 Mar 26. PMID: 26199571; PMCID: PMC4507892.
Copy Download .nbib Format: NLM
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.

Cancers

Rothenberger NJ, Stabile LP.
PMID: 28441771
Cancers (Basel). 2017 Apr 24;9(4). doi: 10.3390/cancers9040039.

Aberrant signaling of the hepatocyte growth factor (HGF)/c-Met pathway has been identified as a promoter of tumorigenesis in several tumor types including head and neck squamous cell carcinoma (HNSCC). Despite a relatively low c-Met mutation frequency, overexpression of HGF...

Cite
Rothenberger NJ, Stabile LP. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers (Basel). 2017;9(4)doi: 10.3390/cancers9040039.
Rothenberger, N. J., & Stabile, L. P. (2017). Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers, 9(4), . https://doi.org/10.3390/cancers9040039
Rothenberger, Natalie J, and Stabile, Laura P. "Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment." Cancers vol. 9,4 (2017). doi: https://doi.org/10.3390/cancers9040039
Rothenberger NJ, Stabile LP. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers (Basel). 2017 Apr 24;9(4). doi: 10.3390/cancers9040039. PMID: 28441771; PMCID: PMC5406714.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 9033 entries